From a practical standpoint, SGLT2 inhibitors should be used for their evidence-based HF benefits regardless of small LDL-C changes, with guideline-directed lipid-lowering therapy optimized in parallel to achieve ApoB- and LDL-C-based targets. The gene discussed is SLC5A2; the disease is hydrops fetalis.